CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
1 - 20 . (canceled).
21 . A method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound of formula:
wherein the cancer is leukemia or lymphoma.
22 . The method of claim 21 , wherein the cancer is leukemia.
23 . The method of claim 21 , wherein the cancer is chronic lymphocytic leukemia (CLL).
24 . The method of claim 21 , wherein the cancer is acute lymphocytic leukemia.
25 . The method of claim 21 , wherein the cancer is acute myelogenous leukemia (AML).
26 . The method of claim 21 , wherein the cancer is chronic myelogenous leukemia (CML).
27 . The method of claim 21 , wherein the cancer is hairy cell leukemia.
28 . The method of claim 21 , wherein the cancer is lymphoma.
29 . The method of claim 21 , wherein the cancer is non-Hodgkin lymphoma.
30 . The method of claim 21 , wherein the cancer is diffuse large B-cell lymphoma.
31 . The method of claim 21 , wherein the cancer is adult T-cell lymphoma.
32 . The method of claim 21 , wherein the cancer is Hodgkin disease.
33 . The method of claim 21 , wherein the cancer is small non-cleaved cell lymphoma.
34 . The method of claim 21 , wherein the cancer is B-cell immunoblastic lymphoma.
35 . The method of claim 21 , further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is bortezomib.
36 . The method of claim 28 , further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is bortezomib.
37 . The method of claim 29 , further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is bortezomib.